Pioglitazone improves visceral sensation and colonic permeability in a rat model of irritable bowel syndrome.
著者
野津, 司
(Nozu, Tsukasa)
宮岸, 沙織
(Miyagishi, Saori)
野津, 麟太郎
(Nozu, Rintaro)
高草木, 薫
(Takakusaki, Kaoru)
奥村, 利勝
(Okumura, Toshikatsu)
上位タイトル
Journal of Pharmacological Sciences
Vol.139,
No.1
(2019.
1)
,p.46-
49
識別番号
ISSN
1347-8613
DOI
10.1016/j.jphs.2018.11.006
その他
PMID：30522964
抄録
Visceral hypersensitivity and impaired gut barrier with minor inflammation are considered to play an important role in the pathophysiology of irritable bowel syndrome (IBS). Since pioglitazone is known to have anti-inflammatory property, we hypothesized that pioglitazone is beneficial for treating IBS. In this study, the effect was tested in rat IBS models such as lipopolysaccharide or repeated water avoidance stress-induced visceral allodynia and increased colonic permeability. Pioglitazone blocked these visceral changes, and GW9662, a peroxisome proliferator-activated receptor gamma (PPAR-γ) antagonist fully reversed the effect by pioglitazone. These results suggest that PPAR-γ activation by pioglitazone may be useful for IBS treatment.
